Epicardial Bradykinin B2 Receptors Elicit a Sympathoexcitatory Reflex in Rats
Abstract
Bradykinin may be generated in the heart during ischemia and is involved in nociception. We tested the hypothesis that bradykinin elicits a sympathoexcitatory reflex in rats by stimulating cardiac afferent nerve fibers. Rats were implanted with femoral catheters for measurement of blood pressure and heart rate, a bipolar electrode for measurement of renal sympathetic nerve activity, and a pericardial catheter for intrapericardial injection of substances. Rats were slightly anesthetized with hexobarbital so pain reactions were prevented. Graded doses of bradykinin (2.5, 12, 25 μg) were injected intravenously or intrapericardially into control rats, intrapericardially after vagotomy, intrapericardially after intrapericardial pretreatment with the bradykinin B2 receptor antagonist Hoe 140, and intrapericardially after cardiac autonomic blockade (intrapericardial pretreatment with 10% procaine). For comparison, the serotonin 5-HT3 agonist phenylbiguanide, a substance known to elicit sympathoinhibitory reflexes by cardiac vagal afferents, and adenosine, putatively inducing sympathoexcitatory responses via the heart, were applied intrapericardially. Bradykinin increased blood pressure when administered intrapericardially but decreased blood pressure when injected intravenously; both intrapericardial and intravenous bradykinin increased renal sympathetic nerve activity. Intrapericardial adenosine had no effect on circulatory control. Intrapericardial pretreatment with the B2 receptor antagonist Hoe 140 completely inhibited the increases of blood pressure and renal sympathetic nerve activity in response to intrapericardial bradykinin but did not affect the responses to intrapericardial phenylbiguanide. Bilateral cervical vagotomy abolished the decreases of blood pressure, heart rate, and renal sympathetic nerve activity after intrapericardial phenylbiguanide but did not influence the responses to intrapericardial bradykinin. Cardiac autonomic blockade with intrapericardial procaine abolished all responses to bradykinin and phenylbiguanide. We conclude that cardiac bradykinin elicits a sympathoexcitatory reflex by epicardial B2 receptors in rats. The afferent portion of the reflex is most likely contained within sympathetic cardiac afferent fibers. Bradykinin may contribute to increased sympathetic nerve activity in pathophysiological situations of coronary artery disease and cardiac ischemia.
Bradykinin is a potent vasodilator of blood vessels in the muscles, kidney, and viscera and also in the coronary circulation.12 Dilatation of systemic arteries causes a sharp fall in systolic and diastolic blood pressures (BPs).3 The substance can increase capillary permeability and produce edema.12 In this respect, it is involved in pain reactions2 and can evoke cardiovascular reflex responses of so far unknown physiological significance.456 In the heart, bradykinin is released in cardiac ischemia and myocardial infarction.7
Important afferent reflex pathways stimulated by bradykinin have their origin in the heart.468910111213 The responses are generally believed to be mediated by cardiac sympathetic afferent fibers. However, there are conflicting reports on decreases and increases in BP, heart rate (HR), and sympathetic nerve activity as well as biphasic responses with respect to these parameters depending on the animal model used.9101114 Especially in the dog, the responses were difficult to predict.9 Vagotomy and sinoaortic denervation were used to avoid putatively confounding reflex responses after cardiac bradykinin application.11 However, vagotomy and sinoaortic denervation may have intrinsic and unpredictable effects on sympathetic outflow.
Bradykinin exerts its effects by stimulation of at least two bradykinin receptors, B1 and B2.1516 B2 receptors are the naturally occurring receptors, and B1 receptors are scarce in normal tissue and expressed in situations of tissue damage.1516171819 Selective B2 receptor antagonists such as Hoe 140 had to be available so that the role in rats of B2 receptors in a putatively sympathoexcitatory circulatory reflex arising from the heart could be addressed.2021
We were interested in the putative ability of bradykinin to induce a sympathoexcitatory response characterized by increases in BP and renal sympathetic nerve activity (RSNA) via B2 receptors in intact rats. To test this hypothesis, we injected bradykinin into the pericardial sac before and after pretreatment with the selective B2 antagonist Hoe 140 to stimulate cardiac afferent fibers. Adenosine, which is said to induce a sympathoexcitatory response by similar reflex mechanisms,422 was used as a positive control. Phenylbiguanide, a serotonin 5-HT3 antagonist that induces hypotension, bradycardia, and sympathoinhibition by stimulating cardiac vagal afferent fibers, was used as a further control.2324 We included cervically vagotomized rats and rats with cardiac autonomic blockade accomplished by instilling 10% procaine into the pericardial sac.
Methods
Male Sprague-Dawley rats (Ivanovas, Kisslegg, FRG) weighing 250 to 300 g were maintained in cages at 24±2°C. They were fed a standard rat diet (No. C-1000, Altromin) containing 0.2% sodium by weight and were allowed free access to tap water.
Preparations
All procedures done in rats were performed in accordance with the guidelines of the American Physiological Society and approved by the local government agency (Regierung von Mittelfranken, Ansbach, FRG). On the day of the experiment and under hexobarbital (30 mg/kg IV, Brevimytal, Eli Lilly) anesthesia, rats were equipped with one femoral arterial and two venous catheters. During the experiments, appropriate anesthesia was achieved with a maintenance infusion of hexobarbital (60 μg/100 g per minute IV) through one of the venous femoral catheters. We used this form of anesthesia to prevent pain reactions during intravenous or intrapericardial administration of bradykinin that might have influenced the response pattern.
Intrapericardial Catheter
As previously described,24 the intrapericardial catheter was constructed from a piece of thin silicone tubing (0.020-inch ID, 0.037-inch OD; Dow Corning) that was formed into an elliptical loop with the longest chord diameter of 2 cm. The loop was fixed with a suture, with the two open ends of the tubing leading out of the tubing being of equal length. One end was used for fluid administration into the pericardial space and the other for fluid withdrawal if more than 30 μL was administered intrapericardially.
Mechanical ventilation was instituted via a tracheal tube, and a high midline thoracotomy was performed. The lobes of the thymus were carefully separated, exposing a small portion of the pericardial sac adherent to the thymus. This part of the pericardial sac was opened, and the loop catheter was inserted into the pericardial sac and advanced toward the left side of the heart. The pericardial sac was closed by apposing the two lobes of the thymus and sealing them together with polyacrylic glue.2425 Finally, the thorax was closed in layers and the open ends of the tubing extensions of the pericardial catheter were exteriorized at the nape. At the end of the respective experiments, 100 μL of concentrated methylene blue in isotonic saline was injected into the pericardial sac via the injection arm; leakage of dye from the pericardial space was assessed visually at autopsy. Only rats without leakage from the pericardial sac were used for final evaluation. The pericardial catheters had a dead space of 4 μL. This amount of saline was used to flush the catheter after injection of substances.
Renal sympathetic nerve recording was performed as described previously.232426 Briefly, the left kidney was exposed through a flank incision, and a renal nerve bundle was dissected and placed on a bipolar stainless steel electrode (Cooner Wire Co). The amplified and filtered signal was channeled to an analog/digital oscilloscope (HM 512, Hameg) and a polygraph (model 7DA, Grass Instrument Co) for visual evaluation. An audio amplifier-loudspeaker (Grass model AM8) was used for auditory evaluation, and a rectifying voltage integrator (Grass model 7P10) was used. The integrated voltage signals were displayed on the polygraph. Fig 1 shows an original tracing. The quality of the RSNA signal was assessed by its pulse synchronous rhythmicity and by examination of the magnitude of the decrease in recorded RSNA during ganglionic blockade with the short-acting ganglionic blocker trimethaphan (10 mg/kg IV) with an injection of methoxamine (10 μg IV). When an optimal signal was observed, the recording electrode was fixed to the nerve bundle with silicone adhesive (Sil-Gel 604, Wacker-Chemie). The electrode cable was then secured to the abdominal trunk muscles by a suture.
For the experiments, the arterial catheter was connected to a transducer (Statham P23 Db) that was connected to a Grass polygraph for recording of BP and HR. A 1-hour equilibration and stabilization period was allowed.
Experimental Protocols
Protocol 1
Six anesthetized and instrumented Sprague-Dawley rats were injected in random order with 25 μg bradykinin either intravenously or intrapericardially. The rats were allowed a 20-minute recovery between each injection.
Protocol 2
Six anesthetized and instrumented Sprague-Dawley rats were injected in random order with 32 μg adenosine IV or 50, 200, and 500 μg adenosine IPC. The rats were allowed a 20-minute recovery between each injection.
Protocol 3
Six anesthetized and instrumented Sprague-Dawley rats were injected with 2.5, 12, and 25 μg bradykinin IPC and 0.9, 9, and 90 μg phenylbiguanide IPC in random order before and after intrapericardial pretreatment with 200 μg of the B2 receptor antagonist Hoe 140. The rats were allowed a 20-minute recovery between each injection. In this and the subsequent protocols, the B2 receptor antagonist was administered in a volume of 40 μL and the bradykinin and phenylbiguanide boluses in portions of 30 μL each.
Protocol 4
Six anesthetized and instrumented Sprague-Dawley rats were injected with 2.5, 12, and 25 μg bradykinin IPC and 0.9, 9, and 90 μg phenylbiguanide IPC in random order before and after bilateral cervical vagotomy performed by cutting the vagus nerves close to the bifurcation of the common carotid arteries. The rats were allowed a 20-minute recovery between each injection. Rats had to be intubated as their respiration was impaired after bilateral cervical vagotomy because the recurrent nerves were also cut.
Protocol 5
Six anesthetized and instrumented Sprague-Dawley rats were injected with 2.5, 12, and 25 μg bradykinin IPC and 0.9, 9, and 90 μg phenylbiguanide IPC in random order before and after intrapericardial pretreatment with 30 μL of 10% procaine. After dose-response curves were obtained without cardiac autonomic blockade first, a 50-μL bolus of 10 μg methoxamine was injected via the second line in the femoral vein to prove proper neurally mediated bradycardia by stimulation of the arterial baroreceptor reflex. BP, HR, and RSNA changes were assessed. A 10% procaine solution (30 μL) was injected into the pericardial sac, and 5 minutes later, methoxamine was given again. After 5 minutes, the methoxamine injection no longer induced reflex bradycardia in rats with properly implanted intrapericardial catheters. This was interpreted as a sign of proper blockade of efferent and afferent cardiac fibers.27282930 Three minutes later, either bradykinin or phenylbiguanide was injected as soon as all parameters had returned to baseline values. Thereafter, a further bolus injection of methoxamine was administered to prove ongoing proper cardiac autonomic blockade. Before each dose of bradykinin and phenylbiguanide, additional injections of 30 μL of 10% procaine into the pericardial sac were necessary because the cardiac autonomic blockade lasted only for 15 minutes. Fluid was removed from the pericardial sac and the methoxamine test repeated again as described above. Since the responses to injections of the highest doses of bradykinin and phenylbiguanide never lasted more than 3.5 minutes, the cardiac autonomic blockade achieved with procaine was sufficient.
Protocol 6
Four anesthetized and instrumented Sprague-Dawley rats were injected with six consecutive doses of 25 μg bradykinin IPC. The drug was given every 20 minutes.
Drugs
Adenosine, bradykinin, methoxamine, phenylbiguanide, and procaine were purchased from Sigma Chemical Co. Trimethaphan camsylate (Arfonad, Hoffmann–La Roche) was provided by Roche Laboratories. The B2 antagonist Hoe 140 was donated courtesy of Dr Schoelkens of Hoechst, Frankfurt, Germany. All drugs except for the previously dissolved trimethaphan were dissolved in saline and prepared anew for every experiment.
Data Analyses
Integrated RSNA was expressed as microvolts integrated over 1-second intervals. The background noise level was recorded as postmortem activity (average of 30 minutes) and subtracted from the measured nerve activity. Because of the limitations of comparing values from multifiber sympathetic nerves between rats, the data are expressed as percent change from control values.
The measured parameters were compared at baseline, maximal response, and recovery before and after drug administration. Furthermore, we tested for possible changes of baseline parameters after administering procaine intrapericardially, cervical vagotomy, or intravenous injection of the B2 receptor antagonist. The data were statistically analyzed by ANOVA and Newman-Keuls post hoc test31 with the CSS statistical software package (StatSoft Inc). Only a priori fixed comparisons were tested. Statistical significance was defined as a value of P<.05. All data are given as mean±SE.
Results
Protocol 1
Protocol 1 evaluated the possibility of distinguishing between intrapericardial and intravenous application of bradykinin by the evoked response pattern in intact rats (Fig 2). Before intrapericardial or intravenous drug administration, baseline BP and HR were 90±6 mm Hg and 400±21 beats per minute (bpm), respectively. ANOVA showed that basal control levels between the injections were not different from these preexperimental values. The two injections were given in random order. Intrapericardial injection of 25 μg bradykinin unequivocally induced marked increases of BP, whereas intravenous application decreased it. The increases in RSNA were nominally not significantly different from each other. HR was not significantly altered after both modes of application. After intrapericardial bradykinin, BP returned to baseline values after 177±9 seconds and RSNA after 184±10 seconds. The time points for intravenous injections of bradykinin were as follows: BP, 175±9 seconds and RSNA, 179±14 seconds.
Protocol 2
Protocol 2 evaluated the effects of intravenous administration of adenosine (32 μg) versus graded intrapericardial application of adenosine (50, 250, 500 μg) on BP, HR, and RSNA responses (Fig 3). Before administration of any drug, baseline BP and HR were 97±6 mm Hg and 388±19 bpm, respectively. ANOVA showed that basal control levels between the various injections were not different from these preexperimental values. Whereas administration of 32 μg adenosine IV led to decreases in BP and HR as well as increases in RSNA, even 500 μg adenosine IPC was not followed by any significant change in the recorded parameters.
Protocol 3
Protocol 3 evaluated the effects of intrapericardial administration of the specific B2 receptor antagonist Hoe 140 on BP, HR, and RSNA responses to graded doses of bradykinin and phenylbiguanide (Figs 1 and 4). Before administration of any drug, baseline BP and HR were 94±6 mm Hg and 380±21 bpm, respectively. ANOVA showed that basal control levels between the various injections were not different from these preexperimental values. Before the administration of the B2 receptor antagonist, bradykinin and phenylbiguanide affected BP, HR, and RSNA dose dependently. Bradykinin increased BP and RSNA, and phenylbiguanide decreased BP, HR, and RSNA. Intrapericardial administration of the B2 receptor antagonist did not affect baseline parameters. After pretreatment with the B2 receptor antagonist, the responses of BP, HR, and RSNA to intrapericardial bradykinin were abolished and those to phenylbiguanide injection were preserved. After the highest dose of bradykinin, BP returned to baseline values after 177±6 seconds and RSNA after 179±13 seconds during the control period. The respective time points for the highest dose of phenylbiguanide were as follows: BP, 176±9 seconds; HR, 162±9 seconds; and RSNA, 185±12 seconds.
Protocol 4
Protocol 4 evaluated the effects of bilateral vagotomy on BP, HR, and RSNA responses to graded doses of bradykinin and phenylbiguanide (Fig 5). Baseline BP and HR assessed before administration of any drug were 97±8 mm Hg and 405±18 bpm, respectively. Again, ANOVA showed that basal control levels between the various injections were not different from these preexperimental values. Before cervical vagotomy was induced, administration of bradykinin and phenylbiguanide affected BP, HR, and RSNA dose dependently as described above. After bilateral cervical vagotomy, the responses to phenylbiguanide were abolished, whereas the responses to bradykinin were unaffected. After the highest dose of bradykinin, BP returned to baseline values after 178±6 seconds and RSNA after 183±9 seconds. The respective time points for the highest dose of phenylbiguanide during the control period were as follows: BP, 173±9 seconds; HR, 162±7 seconds; and RSNA, 183±7 seconds.
Protocol 5
Protocol 5 evaluated the effects of graded doses of bradykinin and phenylbiguanide on BP, HR, and RSNA responses after cardiac autonomic blockade with 10% procaine (Fig 6). Before administration of any drug, baseline BP and HR were 94±6 mm Hg and 380±21 bpm, respectively. ANOVA showed that basal control levels between the various injections were not different from these preexperimental values. During the control period, bradykinin and phenylbiguanide affected BP, HR, and RSNA dose dependently. After the highest dose of bradykinin, BP returned to baseline values after 173±8 seconds and RSNA after 187±10 seconds. The respective time points for the highest dose of phenylbiguanide were as follows: BP, 170±7 seconds; HR, 165±6 seconds; and RSNA, 180±12 seconds. Bradykinin increased BP and RSNA, whereas phenylbiguanide decreased BP, HR, and RSNA. Intrapericardial administration of procaine only transiently affected baseline parameters. Pretreatment with procaine abolished the responses of BP, HR, and RSNA to intrapericardial bradykinin and phenylbiguanide. After the first injection of 10% procaine into the pericardial sac, mean arterial BP was lowered from 94±6 to 88±4 mm Hg for about 5 minutes. HR exhibited only a transient decrease of −32±9 bpm for about 1 minute. RSNA did not change significantly. After cardiac autonomic blockade with intrapericardial procaine, the responses of the measured parameters to both phenylbiguanide and bradykinin were completely inhibited.
Protocol 6
Protocol 6 evaluated the effects of six consecutive doses of 25 μg bradykinin IPC on BP and RSNA responses (Table). Injections were given every 20 minutes. There were no significant changes in the responses of the measured parameters, nor were there significant alterations in the time course of these responses (time of maximal response, time of recovery).
Discussion
Our results demonstrate that cardiac B2 receptors are able to induce a marked sympathoexcitatory response most likely via cardiac sympathetic afferent fibers. Bradykinin given intrapericardially elicited a quite different response of mean arterial BP than when injected intravenously at the same dose: In the first case, BP increased, and in the latter, BP decreased. Intravenous bradykinin is a potent vasodilator.1 Hence, the increases of RSNA after intravenous bradykinin were most likely mediated by the baroreceptor reflex caused by the induced hypotension.3233 However, the increases of RSNA and BP in response to intrapericardial bradykinin should have been mediated by neurogenic mechanisms depending on cardiac afferent nerve traffic.10
It is known that bradykinin stimulates sympathetic afferent fibers from the heart.483435 However, systemic cardiovascular responses have not been uniform and often have been depressant: Excitatory responses have been observed in cats.1436 In rabbits11 and monkeys,9 cardiac bradykinin produced reflex decreases of BP, HR, and sympathetic nerve activity. In dogs, activation of cardiac sympathetic afferents with bradykinin resulted in inhibitory and excitatory as well as biphasic responses.1337
The bradykinin receptor mediating the majority of the bradykinin effects is the B2 receptor.16 In rats, these receptors have been found in the dorsal root ganglia, the spinal cord, and the area close to the cerebral ventricle.383940 These findings suggest that B2 receptors are an important part of visceral autonomous pathways and reflexes.
B1 receptors are synthesized under inflammatory and ischemic conditions.1617 The fact that bradykinin is released especially during myocardial ischemia718 might suggest a role of B1 receptors under these pathophysiological conditions. The existence of a subgroup of cardiac afferent sympathetic fibers synthesizing B1 receptors under special conditions is not completely unlikely.41424344 However, our results in rats demonstrate that cardiac afferent fibers with B2 receptors alone are capable of eliciting a uniform sympathoexcitatory reflex that could instantly influence the neural control of the circulation without the aid of an additional receptor class being partly dependent on de novo synthesis.
The bradykinin inhibitor Hoe 140 proved to be quite specific and did not influence the responses to intrapericardial phenylbiguanide.20 Phenylbiguanide has been shown to be a serotonin 5-HT3 receptor agonist that specifically stimulates cardiac vagal afferents if the drug is injected intrapericardially or intravenously.2324 Both injection routes induced the classic features of the Bezold-Jarisch reflex (hypotension, bradycardia, and sympathoinhibition). On the other hand, intrapericardial bradykinin was characterized by increases of BP and RSNA.
It is assumed that chemostimulation of vagal cardiac afferents induces depressor responses by influencing neural control of the circulation, whereas chemostimulation of cardiac sympathetic afferents may mediate sympathoexcitation and be involved in nociception.8 Bradykinin could theoretically stimulate vagal afferents that are involved in cardiovascular control and nociception. However, in our experiments, vagotomy did not alter the responses to intrapericardial bradykinin. This suggests that the afferent information was most likely transmitted to the central nervous system by sympathetic afferent fibers.
We induced cardiac autonomic blockade by repetitive injections of 10% procaine into the pericardial sac. Several authors have used this method in different animal models.272829304546 Our experiments with intrapericardial procaine demonstrate that the responses to bradykinin and phenylbiguanide injected into the pericardial sac were indeed of cardiac origin.
We used adenosine as a control substance because it occurs endogenously under conditions comparable to those of bradykinin and is also said to stimulate cardiac sympathetic afferent fibers.4 We were not able to elicit any responses by intrapericardial application of adenosine. Since we measured only efferent and not afferent sympathetic nerve activity, it is possible that afferent sympathetic nerve traffic was increased, playing a role in, for instance, nociception but not being involved in the neural control of circulation.8 Since reflex responses to adenosine were observed during acute cardiac ischemia in dogs, these responses of adenosine might depend on facilitating circumstances such as local increases in H+ proton concentration, oxygen free radicals, and/or generation of various mediator substances and related receptors.81643444748 The assumption that adenosine could depend on unknown confounding conditions is further supported by the fact that direct recordings of cardiac sympathetic C fibers showed conflicting results in the same animal model: Whereas Montano et al22 observed marked increases of cardiac sympathetic C-fiber activity after intracoronary injection of adenosine in the cat, Pan and Longhurst36 could detect no response of cardiac sympathetic C fibers after either intracoronary or intrapericardial administration of this drug in cats with coronary ischemia.
Our results demonstrate that local bradykinin can evoke a powerful excitatory reflex. Notably, the sympathoexcitation occurred when all other cardiovascular reflex mechanisms (arterial baroreceptor reflex, cardiopulmonary reflexes with vagal afferents) were left intact and could have compensated. Hence, cardiac B2 receptors might play an important role in circulatory control, when bradykinin is released locally, eg, during cardiac ischemia.
Presented in part at the annual meeting of the American Heart Association, Dallas, Tex, November 14-17, 1994.

Figure 1. Representative recordings of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) in response to 25 μg bradykinin before and after cardiac bradykinin B2 receptor inhibition with Hoe 140.

Figure 2. Responses of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) after intrapericardial or intravenous injection of 25 μg bradykinin.

Figure 3. Responses of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) after intrapericardial (i.p.c.) injection of 32 μg adenosine or intravenous (i.v.) injections of 50, 250, and 500 μg adenosine.

Figure 4. Responses of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) after intrapericardial (ipc) injections of 2.5, 12, and 25 μg bradykinin and 0.9, 9, and 90 μg phenylbiguanide (PBG) before and after intrapericardial administration of the bradykinin B2 receptor antagonist Hoe 140.

Figure 5. Responses of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) after intrapericardial (ipc) injections of 2.5, 12, and 25 μg bradykinin and 0.9, 9, and 90 μg phenylbiguanide (PBG) before and after bilateral cervical vagotomy.

Figure 6. Responses of mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nerve activity (RSNA) after intrapericardial (ipc) injections of 2.5, 12, and 25 μg bradykinin and 0.9, 9, and 90 μg phenylbiguanide (PBG) before and after cardiac autonomic blockade with intrapericardial administration of 10% procaine.
Baseline | Maximal Response | Time of Maximal Response, s | Time of Recovery, s | |
---|---|---|---|---|
Injection 1 | ||||
BP | 96±8 | 30±5 | 99±5 | 166±7 |
RSNA | . . . | 83±6 | 105±5 | 180±7 |
Injection 2 | ||||
BP | 99±7 | 28±4 | 110±12 | 179±4 |
RSNA | . . . | 81±7 | 104±8 | 183±5 |
Injection 3 | ||||
BP | 95±4 | 27±4 | 108±8 | 167±7 |
RSNA | . . . | 82±8 | 112±9 | 179±8 |
Injection 4 | ||||
BP | 97±6 | 28±5 | 112±9 | 173±6 |
RSNA | . . . | 79±5 | 115±7 | 183±5 |
Injection 5 | ||||
BP | 94±6 | 29±4 | 104±13 | 170±4 |
RSNA | . . . | 78±6 | 109±8 | 186±5 |
Injection 6 | ||||
BP | 94±7 | 28±6 | 110±12 | 168±7 |
RSNA | . . . | 78±8 | 106±9 | 183±5 |
This work was supported by a grant-in-aid (Ve104\2-2) from the Deutsche Forschungsgemeinschaft, Bonn-Bad Godesberg, Germany.
Footnotes
References
- 1 Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev.1980; 32:1-47.MedlineGoogle Scholar
- 2 Marceau F, Lussier A, Regoli D, Giroud JP. Pharmacology of kinins: their relevance to tissue injury and inflammation. Gen Pharmacol.1983; 14:209-229.CrossrefMedlineGoogle Scholar
- 3 Margolius HS. Tissue kallikreins and kinins: regulation and role in hypertensive and diabetic diseases. Annu Rev Pharmacol Toxicol.1989; 29:343-364.CrossrefMedlineGoogle Scholar
- 4 Thames MD, Kinugawa T, Dibner-Dunlap ME. Reflex sympathoexcitation by cardiac sympathetic afferents during myocardial ischemia: role of adenosine. Circulation.1993; 87:1698-1704.CrossrefMedlineGoogle Scholar
- 5 Bauer MB, Meller ST, Gebhart GF. Bradykinin modulation of a spinal nociceptive reflex in the rat. Brain Res.1992; 578:186-196.CrossrefMedlineGoogle Scholar
- 6 Evans RG, Ludbrook J, Michalicek J. Use of nicotine, bradykinin and veratridine to elicit cardiovascular chemoreflexes in unanaesthetized rabbits. Clin Exp Pharmacol Physiol.1991; 18:245-254.CrossrefMedlineGoogle Scholar
- 7 Kimura E, Hashimoto K, Furukawa S, Hayakawa H. Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am Heart J.1973; 85:635-647.CrossrefMedlineGoogle Scholar
- 8 Meller ST, Gebhart GF. A critical review of the afferent pathways and the potential chemical mediators involved in cardiac pain. Neuroscience.1992; 48:501-524.CrossrefMedlineGoogle Scholar
- 9 Gorman AJ, Zucker IH, Gilmore JP. Renal nerve responses to cardiac receptor stimulation with bradykinin in monkeys. Am J Physiol.1983; 244:F659-F665.MedlineGoogle Scholar
- 10 Gorman AJ, Zucker IH. Renal nerve and blood pressure responses to stimulation of cardiac receptors in dogs and cats by bradykinin. Basic Res Cardiol.1984; 79:142-154.CrossrefMedlineGoogle Scholar
- 11 Niitani S, Tomomatsu E, Ohba H, Yoshida Y, Yagi S. Renal nerve and cardiovascular responses to cardiac receptor stimulation in rabbits. Am J Physiol.1988; 254:R192-R196.CrossrefMedlineGoogle Scholar
- 12 Armour JA, Yuan BX, Butler CK. Cardiac responses elicited by peptides administered to canine intrinsic cardiac neurons. Peptides.1990; 11:753-761.CrossrefMedlineGoogle Scholar
- 13 Minisi AJ, Thames MD. Distribution of left ventricular sympathetic afferents demonstrated by reflex responses to transmural myocardial ischemia and to intracoronary and epicardial bradykinin. Circulation.1993; 87:240-246.CrossrefMedlineGoogle Scholar
- 14 Reimann KA, Weaver LC. Contrasting reflexes evoked by chemical activation of cardiac afferent nerves. Am J Physiol.1980; 239:H316-H325.MedlineGoogle Scholar
- 15 Sharma JN. Therapeutic prospects of bradykinin receptor antagonists. Gen Pharmacol.1993; 24:267-274.CrossrefMedlineGoogle Scholar
- 16 Regoli D, Jukic D, Gobeil F, Rhaleb NE. Receptors for bradykinin and related kinins: a critical analysis. Can J Physiol Pharmacol.1993; 71:556-567.CrossrefMedlineGoogle Scholar
- 17 Campos AH, Calixto JB. Mechanisms involved in the contractile responses of kinins in rat portal vein rings: mediation by B1 and B2 receptors. J Pharmacol Exp Ther.1994; 268:902-909.MedlineGoogle Scholar
- 18 Chahine R, Adam A, Yamaguchi N, Gaspo R, Regoli D, Nadeau R. Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor. Br J Pharmacol.1993; 108:318-322.CrossrefMedlineGoogle Scholar
- 19 Webb M, McIntyre P, Phillips E. B1 and B2 bradykinin receptors encoded by distinct mRNAs. J Neurochem.1994; 62:1247-1253.MedlineGoogle Scholar
- 20 Linz W, Scholkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol.1992; 105:771-772.CrossrefMedlineGoogle Scholar
- 21 Steranka LR, Farmer SG, Burch RM. Antagonists of B2 bradykinin receptors. FASEB J.1989; 3:2019-2025.CrossrefMedlineGoogle Scholar
- 22 Montano N, Lombardi F, Ruscone TG, Contini M, Guazzi M, Malliani A. Effetto eccitatorio dell'adenosina sull'attivita di scarica delle fibre afferenti simpatiche cardiache. Cardiologia.1991; 36:953-959.MedlineGoogle Scholar
- 23 Veelken R, Hilgers KF, Leonard M, Ruhe J, Scrogin K, Mann JFE, Luft FC. A highly selective cardiorenal, serotonergic 5-HT3-mediated reflex in rats. Am J Physiol.1993; 264:H1871-H1877.MedlineGoogle Scholar
- 24 Veelken R, Sawin LL, DiBona GF. Epicardial 5-HT3 receptors in circulatory control in conscious Sprague Dawley rats. Am J Physiol.1990; 258:H466-H472.MedlineGoogle Scholar
- 25 Veelken R, Schelling P, Unger T. An approach to measuring cardiac output with Doppler flow probes in conscious rats. Am J Physiol.1988; 255:H1206-H1210.MedlineGoogle Scholar
- 26 Veelken R, Sawin LL, DiBona GF. Dissociation of renal nerve and excretory responses to volume expansion in prehypertensive Dahl salt-sensitive and salt-resistant rats. Hypertension.1989; 13:822-827.LinkGoogle Scholar
- 27 Dorward PK, Bell LB, Rudd CD. Cardiac afferents attenuate renal sympathetic baroreceptor reflexes during acute hypertension. Hypertension.1990; 16:131-139.LinkGoogle Scholar
- 28 Dorward PK, Riedel W, Burke SL, Oliver JR, Korner PI. The renal sympathetic baroreflex in the rabbit: arterial and cardiac baroreceptor influences, resetting and the effect of anesthesia. Circ Res.1985; 57:618-633.CrossrefMedlineGoogle Scholar
- 29 Arndt JO, Pasch U, Samodelov LF, Wiebe H. Reversible blockade of myelinated and non-myelinated cardiac fibers in cats by instillation of procaine into the pericardium. Cardiovasc Res.1981; 15:61-67.CrossrefMedlineGoogle Scholar
- 30 Samodelov LF, Pohl M, Arndt JO. Reversible blockade of cardiac efferents with procaine instilled into the pericardium. Cardiovasc Res.1982; 16:187-193.CrossrefMedlineGoogle Scholar
- 31 Wallenstein S, Zucker IH, Fleiss JL. Some statistical methods useful in circulation research. Circ Res.1980; 47:1-9.CrossrefMedlineGoogle Scholar
- 32 Numao Y, Siato M, Terui N, Kumada M. The aortic nerve-sympathetic reflex in the rat. J Auton Nerv Syst.1985; 13:65-79.CrossrefMedlineGoogle Scholar
- 33 Judy WV, Farrell SK. Arterial baroreceptor reflex control of sympathetic nerve activity in the spontaneously hypertensive rat. Hypertension.1979; 1:605-614.LinkGoogle Scholar
- 34 Pan HL, Stebbins CL, Longhurst JC. Bradykinin contributes to the exercise pressor reflex: mechanism of action. J Appl Physiol.1993; 75:2061-2068.CrossrefMedlineGoogle Scholar
- 35 Woolley G, Staszewska Woolley J. A role for cyclic GMP in the initiation of cardiac pressor reflexes by bradykinin and capsaicin. Pol J Pharmacol Pharm.1990; 42:249-257.MedlineGoogle Scholar
- 36 Pan H, Longhurst JC. Lack of a role of adenosine in activation of ischemically sensitive cardiac sympathetic afferents. Am J Physiol.1995; 269:H106-H113.MedlineGoogle Scholar
- 37 Felder RB, Thames MD. Responses to activation of cardiac sympathetic afferents with epicardial bradykinin. Am J Physiol.1982; 242:H148-H153.MedlineGoogle Scholar
- 38 Bauer MB, Simmons ML, Murphy S, Gebhart GF. Bradykinin and capsaicin stimulate cyclic GMP production in cultured rat dorsal root ganglion neurons via a nitrosyl intermediate. J Neurosci Res.1993; 36:280-289.CrossrefMedlineGoogle Scholar
- 39 Lopes P, Regoli D, Couture R. Cardiovascular effects of intrathecally administered bradykinin in the rat: characterization of receptors with antagonists. Br J Pharmacol.1993; 110:1369-1374.CrossrefMedlineGoogle Scholar
- 40 Gerken VM, Santos RA. Centrally infused bradykinin increases baroreceptor reflex sensitivity. Hypertension. 1992;19(suppl II):II-176-II-181.Google Scholar
- 41 Baker DG, Coleridge HM, Coleridge JCG. Vagal afferent C fibers from the ventricle. In: Hainsworth R, Kidd C, Linden RJ, eds. Cardiac Receptors. Cambridge, UK: Cambridge University Press; 1979:117-137.Google Scholar
- 42 Bishop V, Malliani A, Thoren P. Cardiac mechanoreceptors. In: Shepherd JT, Abboud FM, eds. Handbook of Physiology, Section 2: The Cardiovascular System, Volume III, Peripheral Circulation and Organ Blood Flow. Bethesda, Md: American Physiological Society; 1983:497-555.Google Scholar
- 43 Ustinova EE, Schultz HD. Activation of cardiac vagal afferents in ischemia and reperfusion: prostaglandins versus oxygen-derived free radicals. Circ Res.1994; 74:904-911.CrossrefMedlineGoogle Scholar
- 44 Ustinova EE, Schultz HD. Activation of cardiac vagal afferents by oxygen-derived free radicals in rats. Circ Res.1994; 74:895-903.CrossrefMedlineGoogle Scholar
- 45 Ludbrook J, Graham WF. The role of cardiac receptor and arterial baroreceptor reflexes in control of circulation during acute changes of blood volume in the conscious rabbit. Circ Res.1985; 54:424-435.Google Scholar
- 46 Evans RG, Hayes IP, Ludbrook J, Ventura S. Factors confounding blockade of cardiac afferents by intrapericardial procaine in conscious rabbits. Am J Physiol. 1993;264(part 2):H1861-H1870.Google Scholar
- 47 Zanzinger J, Bassenge E. Coronary vasodilation to acetylcholine, adenosine and bradykinin in dogs: effects of inhibition of NO-synthesis and captopril. Eur Heart J. 1993;14(suppl 1):164-168.Google Scholar
- 48 Zanzinger J, Zheng X, Bassenge E. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism. Cardiovasc Res.1994; 28:209-214.CrossrefMedlineGoogle Scholar
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.